Advertisement
Screener

Biofrontera Inc. (BFRI) Fair Value Adjustment of Warrants

2.1 / 5 stars · 19/46 Roast Me

Biofrontera Inc. Fair Value Adjustment of Warrants

Biofrontera Inc. (BFRI) reported Fair Value Adjustment of Warrants of -$44.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13

  • Biofrontera Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$44.00K.
  • Biofrontera Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $219.00K.
  • Biofrontera Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$482.00K.
  • Biofrontera Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $285.00K, a 58.09% decline year-over-year.
  • Biofrontera Inc. fair value adjustment of warrants for fiscal 2025 was -$899.00K.
  • Biofrontera Inc. fair value adjustment of warrants for fiscal 2024 was -$1.68M.
  • Biofrontera Inc. fair value adjustment of warrants for fiscal 2023 was -$6.46M.
  • Biofrontera Inc. fair value adjustment of warrants for fiscal 2022 was -$19.02M.
Period endFair Value Adjustment of Warrants 3 monthFair Value Adjustment of Warrants 3 month as first filedFair Value Adjustment of Warrants 6 monthFair Value Adjustment of Warrants 9 monthFair Value Adjustment of Warrants 9 month as first filedFair Value Adjustment of Warrants 12 monthFair Value Adjustment of Warrants 12 month as first filed
2026-06-30-$44.00K
10-Q · filed 2026-08-13
$175.00K
10-Q · filed 2026-08-13
-$307.00K
derived: sum of 3 quarters · filed 2026-08-13
-$22.00K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$219.00K
10-Q · filed 2026-05-14
-$263.00K
derived: sum of 2 quarters · filed 2026-05-14
$22.00K
derived: sum of 3 quarters · filed 2026-05-14
-$131.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$482.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
-$197.00K
derived: sum of 2 quarters · filed 2026-03-19
-$350.00K
derived: sum of 3 quarters · filed 2026-08-13
-$899.00K
10-K · filed 2026-03-19
2025-09-30$285.00K
10-Q · filed 2025-11-12
$132.00K
derived: sum of 2 quarters · filed 2026-08-13
-$417.00K
10-Q · filed 2025-11-12
-$767.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30-$153.00K
10-Q · filed 2026-08-13
-$702.00K
10-Q · filed 2026-08-13
-$1.05M
derived: sum of 3 quarters · filed 2026-08-13
-$372.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$548.00K
10-Q · filed 2026-05-14
-$899.00K
derived: sum of 2 quarters · filed 2026-05-14
-$219.00K
derived: sum of 3 quarters · filed 2026-05-14
-$5.66M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$351.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$329.00K
derived: sum of 2 quarters · filed 2026-03-19
-$5.11M
derived: sum of 3 quarters · filed 2026-03-19
-$1.68M
10-K · filed 2026-03-19
2024-09-30$680.00K
10-Q · filed 2025-11-12
-$4.76M
derived: sum of 2 quarters · filed 2025-11-12
-$1.33M
10-Q · filed 2025-11-12
-$5.78M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$5.44M
10-Q · filed 2025-08-13
-$2.01M
10-Q · filed 2025-08-13
-$6.46M
derived: sum of 3 quarters · filed 2025-08-13
-$7.06M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$3.43M
10-Q · filed 2025-05-15
-$1.03M
derived: sum of 2 quarters · filed 2025-05-15
-$1.62M
derived: sum of 3 quarters · filed 2025-05-15
-$2.00M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$4.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$5.05M
derived: sum of 2 quarters · filed 2025-03-20
-$5.43M
derived: sum of 3 quarters · filed 2025-03-20
-$6.46M
10-K · filed 2025-03-20
2023-09-30-$598.00K
10-Q · filed 2024-11-14
-$973.00K
derived: sum of 2 quarters · filed 2024-11-14
-$2.00M
10-Q · filed 2024-11-14
-$3.12M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$375.00K
10-Q · filed 2024-08-14
-$1.40M
10-Q · filed 2024-08-14
-$2.52M
derived: sum of 3 quarters · filed 2024-08-14
-$6.34M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$1.03M
10-Q · filed 2024-05-15
-$2.15M
derived: sum of 2 quarters · filed 2024-05-15
-$5.96M
derived: sum of 3 quarters · filed 2024-05-15
-$11.33M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$1.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15
-$4.93M
derived: sum of 2 quarters · filed 2024-03-15
-$10.31M
derived: sum of 3 quarters · filed 2024-03-15
-$19.02M
10-K · filed 2024-03-15
-$16.39M
10-K · filed 2023-03-13
2022-09-30-$3.81M
10-Q · filed 2023-11-09
-$1.19M
10-Q · filed 2022-11-14
-$9.19M
derived: sum of 2 quarters · filed 2023-11-09
-$17.90M
10-Q · filed 2023-11-09
-$15.27M
10-Q · filed 2022-11-14
2022-06-30-$5.37M
10-Q · filed 2023-08-11
-$14.08M
10-Q · filed 2023-08-11
2022-03-31-$8.71M
10-Q · filed 2023-05-12
2021-12-31$12.80M
8-K · filed 2023-10-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Rocket One Inc. (RKTO)United States$0.019B
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Korsana Biosciences, Inc. (CYCN)United States$0.016B